New developments in clinically relevant mechanisms and treatment of hyperuricemia

被引：46

作者：

Lee S.J. ^{[1
]}

Terkeltaub R.A. ^{[1
]}

机构：

[1] University of California, San Diego, Division of Rheumatology, Allergy, and Immunology, Center for Innovative Therapy, San Diego, CA 92037-0943

来源：

Current Rheumatology Reports | 2006年 / 8卷 / 3期

关键词：

Uric Acid; Gout; Losartan; Allopurinol; Hyperuricemia;

D O I：

10.1007/s11926-996-0029-z

中图分类号：

学科分类号：

摘要：

The prevalence of gout has increased markedly in the United States in the past two decades, and new treatments for hyperuricemia are being developed. Recent molecular identification of urate transporter-1 (URAT1) as the central mediator of renal urate reabsorption has provided novel understanding of the pathogenesis of hyperuricemia, and the target site for current and possibly future primary uricosuric agents. Recent studies have also highlighted uricosuric effects of several drugs (losartan, atorvastatin, fenofibrate) that are prescribed for primary indications other than hyperuricemia. The niche of these agents in current management of hyperuricemia is discussed. We also review the ongoing development of recombinant uricase preparations and of novel xanthine oxidase inhibitors exemplified by febuxostat. These agents should provide novel options for patients with chronic, refractory gout and hyperuricemia, particularly in association with allopurinol hypersensitivity and renal insufficiency. Copyright © 2006 by Current Science Inc.

引用

页码：224 / 230

页数：6

共 51 条

[1]

Terkeltaub R.A., Gout, N Engl J Med, 349, pp. 1647-1655, (2003)

[2]

Kim K.Y., Schumacher R., Hunsche E., Et al., A literature review of the epidemiology and treatment of acute gout, Clin Ther, 25, pp. 1593-1617, (2003)

[3]

Bieber J.D., Terkeltaub R.A., Gout: On the brink of novel therapeutic options for an ancient disease, Arthritis Rheum, 50, pp. 2400-2414, (2004)

[4]

Wallace K.L., Riedel A.A., Joseph-Ridge N., Wortmann R., Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population, J Rheumatol, 31, pp. 1582-1587, (2004)

[5]

Wu X., Wakamiya M., Vaishnav S., Et al., Hyperuricemia and urate nephropathy in urate oxidae-deficient mice, Proc Natl Acad Sci U S A, 91, pp. 742-746, (1994)

[6]

Yamanaka H., Togashi R., Hokoda M., Et al., Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment, Adv Exp Med Biol, 431, pp. 13-18, (1998)

[7]

Abbott K.C., Kimmel P.L., Dharnidharka V., Et al., New-onset gout after kidney transplantation: Incidence, risk factors and implications, Transplantation, 80, pp. 1383-1391, (2005)

[8]

Anzai N., Enomoto A., Endou H., Renal urate handling: Clinical relevance of recent advances, Curr Rheum Rep, 7, pp. 227-234, (2005)

[9]

Hediger M.A., Johnson R.J., Miyazaki H., Endou H., Molecular physiology of urate transport, Physiology, 20, pp. 125-133, (2005)

[10]

Enomoto A., Kimura H., Chairoungdua A., Et al., Molecular identification of a renal urate anion exchanger that regulates blood urate levels, Nature, 417, pp. 447-452, (2002)

← 1 2 3 4 5 6 →